BioSpace News Archive

—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to expand Capricor’s manufacturing capacity for potential late-stage clinical trials and commercialization— —Process development to take place in Lonza’s Houston (TX) center of excellence—

Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a research collaboration with AstraZeneca(LSE/STO/Nasdaq: AZN) in a first of its kind study to inform the knowledge base of Neurofibromatosis Type 1 (NF1).

Abbott (NYSE: ABT) is announcing today the fulfillment of the federal government’s order of 150 million BinaxNOW™ COVID-19 Ag tests.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2020.

CardioFocus, Inc ., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference , being held virtually January 11-14, 2021 .

On Friday, December 18, 2020, the team at Natick Family Dental provided free care to over 50 underserved community members – offering everything from cleanings and fillings to dental extractions.

JUD care, a leading high-tech enterprise in the field of smart medical and healthcare solutions, has obtained approval from the US Food and Drug Administration for the portable ward sRoom, a revolutionary solution for patient isolation that enables hospitals to quickly set up emergency isolation rooms.

BIOLASE , Inc. (NASDAQ: BIOL), the global leader in dental lasers announced an agreement with Dental Care Alliance (DCA), one of the largest dental support organizations (DSO) in the United States with more than 330 affiliated practices in 20 states, to expand laser adoption and hands-on training programs in targeted g

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced today that Mark Gelder , M.D., has been promoted to chief medical officer of Elevar Therapeutics.

Liminal BioSciences Inc. (Nasdaq: LMNL) , a clinical-stage biopharmaceutical company, announced that the Company’s wholly-owned subsidiary, Prometic Plasma Resources ( USA ) Inc., has received U.S. Food and Drug Administration approval for its plasma collection